Monaco Asset Management SAM Lowers Position in Ventyx Biosciences, Inc. $VTYX

Monaco Asset Management SAM trimmed its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 70.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 225,603 shares of the company’s stock after selling 536,288 shares during the quarter. Monaco Asset Management SAM’s holdings in Ventyx Biosciences were worth $702,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Affinity Asset Advisors LLC purchased a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at about $9,707,000. Vanguard Group Inc. increased its holdings in shares of Ventyx Biosciences by 19.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock worth $11,725,000 after buying an additional 607,725 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Ventyx Biosciences during the 2nd quarter valued at $5,129,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Ventyx Biosciences by 8.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 945,206 shares of the company’s stock worth $2,023,000 after acquiring an additional 73,601 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of Ventyx Biosciences by 925.6% during the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock worth $1,012,000 after acquiring an additional 794,401 shares during the last quarter. 97.88% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider John Nuss sold 12,675 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the completion of the sale, the insider directly owned 489,481 shares in the company, valued at $3,778,793.32. This represents a 2.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Raju Mohan sold 47,345 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the completion of the sale, the chief executive officer directly owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. This trade represents a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 14.49% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on VTYX shares. Clear Str cut Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 7th. UBS Group reiterated a “neutral” rating and issued a $14.00 price objective (down from $20.00) on shares of Ventyx Biosciences in a report on Thursday, January 8th. Canaccord Genuity Group lowered Ventyx Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $16.00 to $14.00 in a research report on Thursday, January 8th. Wells Fargo & Company restated an “equal weight” rating and issued a $14.00 target price on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Finally, Piper Sandler lowered shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price objective for the company. in a report on Thursday, January 8th. Eight equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $14.00.

Ventyx Biosciences Price Performance

VTYX opened at $13.97 on Friday. The stock’s 50 day simple moving average is $12.17 and its 200 day simple moving average is $7.63. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -9.31 and a beta of 1.25. Ventyx Biosciences, Inc. has a 1 year low of $0.78 and a 1 year high of $25.00.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.